Novartis partners with Science 37 to conduct virtual clinical trials

Novartis AG (NYSE:NVS) and Science 37 Inc. (Los Angeles, Calif.) expanded their collaboration and will now conduct virtual Phase II and Phase III clinical studies, moving

Read the full 268 word article

User Sign In